Radiofrequency For Chronic Knee Pain Post-Arthroplasty (DEFIANT)
Chronic Knee Pain, Osteoarthritis, Knee
About this trial
This is an interventional treatment trial for Chronic Knee Pain focused on measuring Genicular Radiofrequency Ablation, Knee Arthroplasty, Total
Eligibility Criteria
Inclusion Criteria:
- Study candidate must provide written informed consent.
- Must be ≥ 50 years of age at the time of consent
- Chronic knee pain despite total knee arthroplasty at least 6 months prior to consent
- Orthopedic evaluation indicating no further surgery is warranted
- Stable pain medication regimen for 30 days prior to baseline visit
- Knee pain is primary pain complaint
Exclusion Criteria:
- Acute knee pain
- Connective tissue disorders affecting the knee
- Serious neurologic or psychiatric disorders that would affect the outcome of the study as determined by the Principal Investigator
- Steroid or hyaluronic acid injections into the affected knee in the past 3 months
- Confounding pain conditions of the index leg that may affect medication requirements or study outcomes
Sites / Locations
- WK River Cities Clinical Research Center
Arms of the Study
Arm 1
Arm 2
Active Comparator
Sham Comparator
Nerve Block with Radiofrequency Ablation
Nerve Block with Sham Radiofrequency Ablation
A 10 cm 18-gauge RF cannula with a 10 mm active tip will be placed at the superior lateral, superior medial, and inferior medial nerve positions under fluoroscopic guidance. Sensory stimulation at 50 Hz will be performed to identify nerve position and to assure no motor nerves will be ablated. Lidocaine (2 ml of 2%) will be administered in each location prior to RF generator activation.
A 10 cm 18-gauge RF cannula with a 10 mm active tip will be placed at the superior lateral, superior medial, and inferior medial nerve positions under fluoroscopic guidance.Control patients will undergo the same procedure without RF generator activation. Sensory stimulation at 50 Hz will be performed to identify nerve position and to assure no motor nerves will be ablated. Lidocaine (2 ml of 2%) will be administered in each location prior to RF generator sham activation.